NIOX Group (LON:NIOX) Trading 2.7% Higher – Should You Buy?

NIOX Group Plc (LON:NIOX) shares were up 2.7% on Friday . The stock traded as high as GBX 68.20 and last traded at GBX 68. Approximately 27,558 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 1,076,437 shares. The stock had previously closed at GBX 66.20.

NIOX Group Stock Performance

The stock has a 50-day simple moving average of GBX 69.54 and a 200-day simple moving average of GBX 70.13. The company has a debt-to-equity ratio of 1.10, a current ratio of 6.31 and a quick ratio of 1.94. The stock has a market cap of £284.16 million, a PE ratio of 54.40 and a beta of 0.92.

NIOX Group (LON:NIOX) last released its quarterly earnings data on Tuesday, September 30th. The company reported GBX 1.43 EPS for the quarter. NIOX Group had a return on equity of 13.29% and a net margin of 28.21%. Equities analysts predict that NIOX Group Plc will post 1.1658256 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other NIOX Group news, insider Sarah Duncan acquired 5,522 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was bought at an average cost of GBX 71 per share, for a total transaction of £3,920.62. 4.88% of the stock is currently owned by company insiders.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.